Citadel Advisors’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $27.2M | Sell |
572,300
-185,900
| -25% | -$9.81M | ﹤0.01% | 1957 |
|
|
2025
Q4 | $39.8M | Sell |
758,200
-129,800
| -15% | -$7.77M | 0.01% | 1633 |
|
|
2025
Q3 | $57.6M | Buy |
888,000
+594,600
| +203% | +$34.1M | 0.01% | 1252 |
|
|
2025
Q2 | $14.3M | Sell |
293,400
-119,300
| -29% | -$4.62M | ﹤0.01% | 2579 |
|
|
2025
Q1 | $14M | Sell |
412,700
-381,000
| -48% | -$16.2M | ﹤0.01% | 2439 |
|
|
2024
Q4 | $31.2M | Buy |
793,700
+98,300
| +14% | +$4.64M | 0.01% | 1708 |
|
|
2024
Q3 | $32.7M | Sell |
695,400
-15,400
| -2% | -$781K | 0.01% | 1597 |
|
|
2024
Q2 | $38.4M | Sell |
710,800
-124,300
| -15% | -$7.19M | 0.01% | 1365 |
|
|
2024
Q1 | $56.9M | Sell |
835,100
-315,400
| -27% | -$22.6M | 0.01% | 1108 |
|
|
2023
Q4 | $72M | Buy |
1,150,500
+759,400
| +194% | +$42M | 0.01% | 894 |
|
|
2023
Q3 | $17.8M | Sell |
391,100
-16,600
| -4% | -$857K | ﹤0.01% | 1988 |
|
|
2023
Q2 | $22.9M | Buy |
407,700
+221,900
| +119% | +$12.6M | ﹤0.01% | 1744 |
|
|
2023
Q1 | $8.4M | Sell |
185,800
-281,100
| -60% | -$13.7M | ﹤0.01% | 3034 |
|
|
2022
Q4 | $19M | Buy |
466,900
+239,100
| +105% | +$12.7M | ﹤0.01% | 2021 |
|
|
2022
Q3 | $14.9M | Sell |
227,800
-288,100
| -56% | -$20.9M | ﹤0.01% | 2230 |
|
|
2022
Q2 | $31.4M | Buy |
515,900
+45,400
| +10% | +$2.67M | 0.01% | 1434 |
|
|
2022
Q1 | $29.5M | Buy |
470,500
+105,900
| +29% | +$6.65M | 0.01% | 1569 |
|
|
2021
Q4 | $27.6M | Sell |
364,600
-33,000
| -8% | -$2.88M | 0.01% | 1682 |
|
|
2021
Q3 | $44.5M | Sell |
397,600
-62,300
| -14% | -$7.82M | 0.01% | 1227 |
|
|
2021
Q2 | $74.5M | Buy |
459,900
+95,200
| +26% | +$11.6M | 0.02% | 844 |
|
|
2021
Q1 | $44.4M | Buy |
364,700
+134,400
| +58% | +$20.3M | 0.01% | 1142 |
|
|
2020
Q4 | $35.3M | Buy |
230,300
+149,400
| +185% | +$17.7M | 0.01% | 1248 |
|
|
2020
Q3 | $6.77M | Sell |
80,900
-18,100
| -18% | -$1.61M | ﹤0.01% | 2741 |
|
|
2020
Q2 | $7.28M | Buy |
99,000
+15,800
| +19% | +$924K | ﹤0.01% | 2581 |
|
|
2020
Q1 | $3.53M | Buy |
83,200
+6,400
| +8% | +$330K | ﹤0.01% | 3209 |
|
|
2019
Q4 | $4.68M | Buy |
76,800
+42,400
| +123% | +$2.31M | ﹤0.01% | 3160 |
|
|
2019
Q3 | $1.41M | Sell |
34,400
-4,900
| -12% | -$234K | ﹤0.01% | 5034 |
|
|
2019
Q2 | $1.85M | Sell |
39,300
-4,900
| -11% | -$196K | ﹤0.01% | 4640 |
|
|
2019
Q1 | $1.58M | Sell |
44,200
-61,700
| -58% | -$2.13M | ﹤0.01% | 4846 |
|
|
2018
Q4 | $3.03M | Buy |
105,900
+28,000
| +36% | +$973K | ﹤0.01% | 3498 |
|
|
2018
Q3 | $3.46M | Sell |
77,900
-10,600
| -12% | -$555K | ﹤0.01% | 3515 |
|
|
2018
Q2 | $5.2M | Buy |
88,500
+8,000
| +10% | +$456K | ﹤0.01% | 2725 |
|
|
2018
Q1 | $3.68M | Buy |
+80,500
| New | +$3.32M | ﹤0.01% | 2853 |
|
Other funds holding CRSP
AIM
OAG
GP
SOCM
Citadel Advisors's CRSP Position: Q1 2026 in Review
Citadel Advisors increased its CRISPR Therapeutics (CRSP) stake by 93% in Q1 2026, buying an estimated $13.1M and bringing the position to 516,352 shares worth $24.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2082.
Citadel Advisors first reported a position in CRSP in Q4 2017 and has held it in 31 quarters since. The position peaked at $34.6M in Q4 2024. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.
- Citadel Advisors held 516,352 shares of CRISPR Therapeutics worth $24.6M as of Q1 2026.
- Citadel Advisors bought 248,667 CRISPR Therapeutics shares in Q1 2026, an estimated $13.1M.
- CRISPR Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #2082 holding.
- Citadel Advisors first reported a position in CRISPR Therapeutics in Q4 2017 and has held it in 31 quarters since.
- Citadel Advisors's CRISPR Therapeutics position peaked at $34.6M in Q4 2024.
- 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.